Comparison of pancreatic beta cells and alpha cells under hyperglycemia: Inverse coupling in pAkt-FoxO1. 2017

Mi-Kyung Kim, and Hyun Mi Shin, and HyeSook Jung, and EunJu Lee, and Tae Kyoon Kim, and Tae Nyun Kim, and Min Jeong Kwon, and Soon Hee Lee, and Byoung Doo Rhee, and Jeong Hyun Park
Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, Inje University, Busan, South Korea; Paik Institute for Clinical Research, Molecular Therapy Lab, Inje University, Busan, South Korea. Electronic address: kmkdoc@paik.ac.kr.

Type 2 diabetes manifests beta cell deficiencies and alpha cell expansion which is consistent with relative insulin deficiency and glucagon oversecretion. The effects of hyperglycemia on alpha cells are not as understood in comparison to beta cells. Hyperglycemia increases oxidative stress, which induces Akt activation or FoxO activation, depending on cell type. Several studies independently reported that FoxO1 translocations in alpha cells and beta cells were opposite. We compared the responses of pancreatic alpha cells and beta cells against hyperglycemia. Alpha TC-1 cells and Beta TC-6 cells were incubated with control (5mM Glucose) or high glucose (33mM Glucose) with or without PI3K inhibitor or FoxO1 inhibitor. We assessed PI3K, pAkt and phosphorylated FoxO1 (pFoxO1) in both cell lines. Immunostaining of BrdU and FoxO1 was detected by green fluorescence microscopy and confocal microscopy. Hyperglycemia and H2O2 decreased PI3K and pAKT in beta cells, but increased them in alpha cells. FoxO1 localizations and pFoxO1 expressions between alpha cells and beta cells were opposite. Proliferation of beta cells was decreased, but alpha cell proliferation was increased under hyperglycemia. Antioxidant enzymes including superoxide dismutase (SOD) and catalase were increased in beta cells and they were reversed with FoxO1 inhibitor treatment. Increased proliferation in alpha cells under hyperglycemia was attenuated with PI3K inhibitor. In conclusion, hyperglycemia increased alpha cell proliferation and glucagon contents which are opposite to beta cells. These differences may be related to contrasting PI3K/pAkt changes in both cells and subsequent FoxO1 modulation.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D007340 Insulinoma A benign tumor of the PANCREATIC BETA CELLS. Insulinoma secretes excess INSULIN resulting in HYPOGLYCEMIA. Adenoma, beta-Cell,Insuloma,beta-Cell Tumor,Adenoma, beta Cell,Adenomas, beta-Cell,Insulinomas,Insulomas,Tumor, beta-Cell,Tumors, beta-Cell,beta Cell Tumor,beta-Cell Adenoma,beta-Cell Adenomas,beta-Cell Tumors
D010190 Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA). Cancer of Pancreas,Pancreatic Cancer,Cancer of the Pancreas,Neoplasms, Pancreatic,Pancreas Cancer,Pancreas Neoplasms,Pancreatic Acinar Carcinoma,Pancreatic Carcinoma,Acinar Carcinoma, Pancreatic,Acinar Carcinomas, Pancreatic,Cancer, Pancreas,Cancer, Pancreatic,Cancers, Pancreas,Cancers, Pancreatic,Carcinoma, Pancreatic,Carcinoma, Pancreatic Acinar,Carcinomas, Pancreatic,Carcinomas, Pancreatic Acinar,Neoplasm, Pancreas,Neoplasm, Pancreatic,Neoplasms, Pancreas,Pancreas Cancers,Pancreas Neoplasm,Pancreatic Acinar Carcinomas,Pancreatic Cancers,Pancreatic Carcinomas,Pancreatic Neoplasm
D010766 Phosphorylation The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety. Phosphorylations
D003924 Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. Diabetes Mellitus, Adult-Onset,Diabetes Mellitus, Ketosis-Resistant,Diabetes Mellitus, Maturity-Onset,Diabetes Mellitus, Non-Insulin-Dependent,Diabetes Mellitus, Slow-Onset,Diabetes Mellitus, Stable,MODY,Maturity-Onset Diabetes Mellitus,NIDDM,Diabetes Mellitus, Non Insulin Dependent,Diabetes Mellitus, Noninsulin Dependent,Diabetes Mellitus, Noninsulin-Dependent,Diabetes Mellitus, Type II,Maturity-Onset Diabetes,Noninsulin-Dependent Diabetes Mellitus,Type 2 Diabetes,Type 2 Diabetes Mellitus,Adult-Onset Diabetes Mellitus,Diabetes Mellitus, Adult Onset,Diabetes Mellitus, Ketosis Resistant,Diabetes Mellitus, Maturity Onset,Diabetes Mellitus, Slow Onset,Diabetes, Maturity-Onset,Diabetes, Type 2,Ketosis-Resistant Diabetes Mellitus,Maturity Onset Diabetes,Maturity Onset Diabetes Mellitus,Non-Insulin-Dependent Diabetes Mellitus,Noninsulin Dependent Diabetes Mellitus,Slow-Onset Diabetes Mellitus,Stable Diabetes Mellitus
D005934 Glucagon A 29-amino acid pancreatic peptide derived from proglucagon which is also the precursor of intestinal GLUCAGON-LIKE PEPTIDES. Glucagon is secreted by PANCREATIC ALPHA CELLS and plays an important role in regulation of BLOOD GLUCOSE concentration, ketone metabolism, and several other biochemical and physiological processes. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1511) Glucagon (1-29),Glukagon,HG-Factor,Hyperglycemic-Glycogenolytic Factor,Proglucagon (33-61),HG Factor,Hyperglycemic Glycogenolytic Factor
D005947 Glucose A primary source of energy for living organisms. It is naturally occurring and is found in fruits and other parts of plants in its free state. It is used therapeutically in fluid and nutrient replacement. Dextrose,Anhydrous Dextrose,D-Glucose,Glucose Monohydrate,Glucose, (DL)-Isomer,Glucose, (alpha-D)-Isomer,Glucose, (beta-D)-Isomer,D Glucose,Dextrose, Anhydrous,Monohydrate, Glucose
D006861 Hydrogen Peroxide A strong oxidizing agent used in aqueous solution as a ripening agent, bleach, and topical anti-infective. It is relatively unstable and solutions deteriorate over time unless stabilized by the addition of acetanilide or similar organic materials. Hydrogen Peroxide (H2O2),Hydroperoxide,Oxydol,Perhydrol,Superoxol,Peroxide, Hydrogen
D006943 Hyperglycemia Abnormally high BLOOD GLUCOSE level. Postprandial Hyperglycemia,Hyperglycemia, Postprandial,Hyperglycemias,Hyperglycemias, Postprandial,Postprandial Hyperglycemias
D000071161 Forkhead Box Protein O1 A forkhead box transcription factor that is a major target of INSULIN signaling and regulator of metabolic homeostasis in response to OXIDATIVE STRESS. It binds to the insulin RESPONSE ELEMENT (IRE) and the related Daf-16 family binding element (DBE). Its activity is suppressed by insulin and it also regulates OSTEOBLAST proliferation, controls bone mass, and skeletal regulation of GLUCOSE metabolism. It promotes GLUCONEOGENESIS in HEPATOCYTES and regulates gene expression in ADIPOSE TISSUE. It is also an important CELL DEATH regulator. Chromosomal aberrations involving the FOXO1 gene occur in RHABDOMYOSARCOMA. FOXO1 Protein,Forkhead in Rhabdomyosarcoma Protein

Related Publications

Mi-Kyung Kim, and Hyun Mi Shin, and HyeSook Jung, and EunJu Lee, and Tae Kyoon Kim, and Tae Nyun Kim, and Min Jeong Kwon, and Soon Hee Lee, and Byoung Doo Rhee, and Jeong Hyun Park
January 1991, Experimental pathology,
Mi-Kyung Kim, and Hyun Mi Shin, and HyeSook Jung, and EunJu Lee, and Tae Kyoon Kim, and Tae Nyun Kim, and Min Jeong Kwon, and Soon Hee Lee, and Byoung Doo Rhee, and Jeong Hyun Park
January 1994, Journal of cellular biochemistry,
Mi-Kyung Kim, and Hyun Mi Shin, and HyeSook Jung, and EunJu Lee, and Tae Kyoon Kim, and Tae Nyun Kim, and Min Jeong Kwon, and Soon Hee Lee, and Byoung Doo Rhee, and Jeong Hyun Park
December 2016, Diabetologia,
Mi-Kyung Kim, and Hyun Mi Shin, and HyeSook Jung, and EunJu Lee, and Tae Kyoon Kim, and Tae Nyun Kim, and Min Jeong Kwon, and Soon Hee Lee, and Byoung Doo Rhee, and Jeong Hyun Park
April 1996, Endocrinology,
Mi-Kyung Kim, and Hyun Mi Shin, and HyeSook Jung, and EunJu Lee, and Tae Kyoon Kim, and Tae Nyun Kim, and Min Jeong Kwon, and Soon Hee Lee, and Byoung Doo Rhee, and Jeong Hyun Park
January 2010, Gaceta medica de Mexico,
Mi-Kyung Kim, and Hyun Mi Shin, and HyeSook Jung, and EunJu Lee, and Tae Kyoon Kim, and Tae Nyun Kim, and Min Jeong Kwon, and Soon Hee Lee, and Byoung Doo Rhee, and Jeong Hyun Park
February 2006, PLoS biology,
Mi-Kyung Kim, and Hyun Mi Shin, and HyeSook Jung, and EunJu Lee, and Tae Kyoon Kim, and Tae Nyun Kim, and Min Jeong Kwon, and Soon Hee Lee, and Byoung Doo Rhee, and Jeong Hyun Park
March 1991, Science (New York, N.Y.),
Mi-Kyung Kim, and Hyun Mi Shin, and HyeSook Jung, and EunJu Lee, and Tae Kyoon Kim, and Tae Nyun Kim, and Min Jeong Kwon, and Soon Hee Lee, and Byoung Doo Rhee, and Jeong Hyun Park
September 2012, Genes to cells : devoted to molecular & cellular mechanisms,
Mi-Kyung Kim, and Hyun Mi Shin, and HyeSook Jung, and EunJu Lee, and Tae Kyoon Kim, and Tae Nyun Kim, and Min Jeong Kwon, and Soon Hee Lee, and Byoung Doo Rhee, and Jeong Hyun Park
January 2023, Laboratory investigation; a journal of technical methods and pathology,
Mi-Kyung Kim, and Hyun Mi Shin, and HyeSook Jung, and EunJu Lee, and Tae Kyoon Kim, and Tae Nyun Kim, and Min Jeong Kwon, and Soon Hee Lee, and Byoung Doo Rhee, and Jeong Hyun Park
February 1979, Medical biology,
Copied contents to your clipboard!